- Home
- WLY vs PTGX Comparison
WLY vs PTGX Comparison
Compare WLY & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLY
- PTGX
- Stock Information
- Founded
- WLY 1807
- PTGX 2006
- Country
- WLY United States
- PTGX United States
- Employees
- WLY N/A
- PTGX N/A
- Industry
- WLY Books
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- WLY Consumer Discretionary
- PTGX Health Care
- Exchange
- WLY Nasdaq
- PTGX Nasdaq
- Market Cap
- WLY 2.3B
- PTGX 2.8B
- IPO Year
- WLY N/A
- PTGX 2016
- Fundamental
- Price
- WLY $43.56
- PTGX $44.49
- Analyst Decision
- WLY
- PTGX Strong Buy
- Analyst Count
- WLY 0
- PTGX 8
- Target Price
- WLY N/A
- PTGX $66.50
- AVG Volume (30 Days)
- WLY 346.8K
- PTGX 1.3M
- Earning Date
- WLY 06-12-2025
- PTGX 05-06-2025
- Dividend Yield
- WLY 3.25%
- PTGX N/A
- EPS Growth
- WLY N/A
- PTGX N/A
- EPS
- WLY 0.75
- PTGX 4.23
- Revenue
- WLY $1,703,491,000.00
- PTGX $434,433,000.00
- Revenue This Year
- WLY N/A
- PTGX N/A
- Revenue Next Year
- WLY $1.13
- PTGX $7.13
- P/E Ratio
- WLY $57.90
- PTGX $10.55
- Revenue Growth
- WLY N/A
- PTGX 624.05
- 52 Week Low
- WLY $34.85
- PTGX $24.22
- 52 Week High
- WLY $53.96
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- WLY 53.34
- PTGX 45.83
- Support Level
- WLY $42.74
- PTGX $45.07
- Resistance Level
- WLY $44.12
- PTGX $47.35
- Average True Range (ATR)
- WLY 1.49
- PTGX 2.42
- MACD
- WLY 0.10
- PTGX -0.05
- Stochastic Oscillator
- WLY 88.29
- PTGX 56.08
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.